SyntekaBio

SyntekaBio Shareholder Yield

Shareholder Yield of SyntekaBio (226330.KQ) as of Nov 20, 2026.

Shareholder Yield

0.00

Last updated:

Shareholder Yield of SyntekaBio is 2025 0.00 . Shareholder Yield of SyntekaBio was 2024 0.33 % . It decreases by % lower compared to the previous year.

The SyntekaBio Shareholder Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shareholder Yield
Date
Shareholder Yield
Jan 1, 2018
0.51 KRW
Jan 1, 2019
49.30 KRW
Jan 1, 2020
2.10 KRW
Jan 1, 2021
0.52 KRW
Jan 1, 2022
0.22 KRW
Jan 1, 2023
0.02 KRW
Jan 1, 2024
0.33 KRW
Jan 1, 2025
0.00 KRW
The SyntekaBio Shareholder Yield history
YEARShareholder YieldYoY
0.00-100.00%
0.33 %+2,083.33%
0.02 %-93.11%
0.22 %-57.95%
0.52 %-75.01%
2.10 %-95.75%
49.30 %+9,484.96%
0.51 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

On Eulerpool you can find the complete historical development of Shareholder Yield SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Shareholder yield combines dividend yield and buyback yield to show the total cash return to shareholders. It captures both dividends and share repurchases.

To evaluate Shareholder Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Shareholder Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Shareholder Yield's SyntekaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SyntekaBio

All Key Metrics — SyntekaBio